Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
English
Français
Canada
Sandoz Site Directory
Our Work
What We Do
Quality Generics
Biopharmaceuticals
Specialty Products
About Us
Who We Are
Corporate Responsibility
Doing Business Responsibly
Contact Us
Grants, Donations and Sponsorships
Products
Consumers
Patients
Healthcare Professionals
Patient Support Programs
News
Media Releases
Media Resource Center
Stay Up-To-Date
Careers
Available Positions
Join the Sandoz Manufacturing team in Boucherville
Our Benefits
Employee Testimonials
Our Values and Vision
Diversity & Inclusion
Search
Global Impact
Medicines
Discovery
Hope
Global Impact
Education & Awareness
Global Impact
Subscribe
Third consecutive recognition for Novartis in Canada as a Great Place to Work®
Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz® (adalimumab)
Sandoz Canada launches the first generic versions of two original drugs: PrSandoz® Posaconazole and PrSandoz® Silodosin
2021 Top Employer Canada
London Drugs Award 2020
Biosimilars reimbursement update
Coronavirus
Biosimilars switch policies update: British Columbia expands its Biosimilars Initiative to include rituximab
Novartis in Canada, including Sandoz Canada, initiates Community Strong COVID-19 response program
1 of 3
››
